杂色
发表于 2025-3-30 10:38:19
Genetic Changes in Breast Cancer,the timing and degree of exposure to hormones and growth factors, such as age of menarche, menopause, first pregnancy, and breast feeding (Lipmman and Dickson, 1988). In addition, approx 5% of all. breast cancers are clustered in families that have a high incidence of early onset of the disease (Hall et al., 1990).
负担
发表于 2025-3-30 12:54:58
http://reply.papertrans.cn/23/2231/223009/223009_52.png
狂热文化
发表于 2025-3-30 20:11:10
http://reply.papertrans.cn/23/2231/223009/223009_53.png
AGONY
发表于 2025-3-31 00:47:25
https://doi.org/10.1007/978-3-322-93929-6 into different risk groups. This, in turn, can contribute to the development of new methods for detecting cancer and for identifying genetic susceptibility and/or predisposition to cancer, as well as for improving predictions of clinical outcome and providing avenues for new therapies. Gynecological malignancies are no exception.
HEED
发表于 2025-3-31 01:37:28
Objektorientierte Programmierung in JAVA% (Miller et al., 1992a). As a result, lung cancer is the chief cause of cancer mortality in both men and women, accounting for an estimated 153,000 cancer deaths in 1994 (Boring et al., 1994). Further, lung cancer is likely to remain a leading cause of both cancer incidence and cancer mortality well into the next century (Gaffney et al., 1988).
一致性
发表于 2025-3-31 07:54:27
http://reply.papertrans.cn/23/2231/223009/223009_56.png
做作
发表于 2025-3-31 09:20:27
http://reply.papertrans.cn/23/2231/223009/223009_57.png
Cleave
发表于 2025-3-31 14:52:55
https://doi.org/10.1007/978-3-322-94096-4rent hybridoma methodology. Furthermore, the MAb developed may not have the affinity needed for a given function, or the MAb’s isotype may not be optimal for the desired effector function, for example, antibody-dependent cell-mediated cytotoxicity (ADCC).
特别容易碎
发表于 2025-3-31 20:29:59
http://reply.papertrans.cn/23/2231/223009/223009_59.png
LAITY
发表于 2025-3-31 22:00:55
Oncogenes and Tumor-Suppressor Genes in Gynecological Malignancies, into different risk groups. This, in turn, can contribute to the development of new methods for detecting cancer and for identifying genetic susceptibility and/or predisposition to cancer, as well as for improving predictions of clinical outcome and providing avenues for new therapies. Gynecological malignancies are no exception.